142128-57-2
Chemical Structure
Levoketoconazole
Synonym(s): (-)-Ketoconazole;(-)-Ketoconazol;(-)-R 41400
- CAS No.: 142128-57-2
- Formula:C26H28Cl2N4O4
- Molecular Weight:531.43
IUPAC Name: 1-(4-(4-(((2S,4R)-2-((1H-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)ethan-1-one
InChIKey: XMAYWYJOQHXEEK-ZEQKJWHPSA-N
SMILES: CC(N1CCN(C2=CC=C(OC[C@H]3O[C@](CN4C=CN=C4)(C5=CC=C(Cl)C=C5Cl)OC3)C=C2)CC1)=O
Biological Activity: Levoketoconazole ((-)-Ketoconazole) is the 2S,4R enantiomer derived from racemic Ketoconazole (HY-B0105). Levoketoconazole is a potent and orally active cortisol synthesis inhibitor. Levoketoconazole inhibits key steps in cortisol and testosterone synthesis by inhibiting CYP11B1, CYP11A1, and CYP17A1. Levoketoconazole can be used for research on endogenous Cushing’s syndrome[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Levoketoconazole | 99.82% | Levoketoconazole ((-)-Ketoconazole) is the 2S,4R enantiomer derived from racemic Ketoconazole (HY-B0105). Levoketoconazole is a potent and orally active cortisol synthesis inhibitor. Levoketoconazole inhibits key steps in cortisol and testosterone synthesis by inhibiting CYP11B1, CYP11A1, and CYP17A1. Levoketoconazole can be used for research on endogenous Cushing’s syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-137372Arel-trans-Ketoconazole -
Similarity Score 1.00
HY-B0105A(+)-Ketoconazole -
Similarity Score 1.00
HY-B0105RKetoconazole (Standard) -
Similarity Score 1.00
HY-W422288(Rac)-Ketoconazole -
Similarity Score 0.90
HY-B0105BSLevoketoconazole-d3 -
Similarity Score 0.89
HY-121069Elubiol -
Similarity Score 0.85
HY-129315Deacylketoconazole -
Similarity Score 0.84
HY-Z19683Ketoconazole impurity 2 -
Similarity Score 0.79
HY-B0105S1Ketoconazole-d4 -
Explore the MedChemAI to find more analogs
References
- [1]. Pivonello R, et al. Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary. 2022 Dec;25(6):911-926. [Content Brief]
- [2]. McCartney NK, et al. Levoketoconazole. Hosp Pharm. 2022 Oct;57(5):605-614. [Content Brief]